Unum Therapeutics Inc (NASDAQ:UMRX) Q1 2019 Earnings Conference Call Transcript
May 13, 2019 • 08:00 am ET
Good day, ladies and gentlemen, and welcome to the Unum Therapeutics First Quarter 2019 Results Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Stephanie Ascher. Ma'am, you may begin.
Good morning and welcome to the Unum Therapeutics quarterly investor conference call. Today, we'll be sharing updates on our Company's progress and our financial results for the first quarter ended March 31, 2019. With me on our call today are Chuck Wilson, Chief Executive Officer; Michael Vasconcelles, Chief Medical Officer; Seth Ettenberg, Chief Scientific Officer; and John Green, Vice President of Finance. Following our prepared remarks, we'll open the line for questions.
Before we begin, I need to remind you that estimates and other forward-looking statements included in this call represent the Company's view as of today, May 13, 2019. Unum Therapeutics disclaims any obligation to update these statements to reflect future events or circumstances. Please refer to today's press release as well as Unum's filings with the SEC for information concerning risk factors that could cause actual results to differ materially from those expressed or implied by such statements. Please also note that this call is being simultaneously webcast online.
With that, let me introduce Chuck Wilson. Chuck?
Good morning. I'm glad you're able to join us for our first quarter earnings call. Today, we'll provide a quick snapshot of where we stand as we continue to advance our pipeline of programs. Mike will give an update on our four ongoing clinical trials, and Seth will talk about our current research efforts to expand our technology platform with a particular focus on targeting solid tumors. We'll then conclude with a summary of our financial performance by John. We remain on track to deliver on key milestones across our pipeline of hematologic and solid tumor programs. In our program targeting hematological cancers, we're continuing dose escalation with the objective of establishing potential best in class product profiles that may compete effectively with other approved and investigational products.
In our solid tumor programs, our two technology platforms, ACTR and BOXR, are well positioned to address many of the efficacy and safety challenges faced by T-cell therapies. As a reminder, we've evaluated two different ACTR product candidates, ACTR707 and ACTR087, in combination with rituximab to treat patients with relapsed/refractory non-Hodgkin lymphoma. These trials have been very important for us in providing clinical proof-of-concept for the ACTR technology. At the end of last year, we selected ACTR707 as our lead to move forward and announced our decision to wind up the ACTR087 program. We've made progress since then on both fronts, as Mike will describe in more detail.
Importantly, we've now escalated through four dose levels with ACTR707. And as of last week, we've seen no dose-limiting toxicities. As part of our collaboration with Seattle Genetics